When was $REPL first mentioned on Surfaced?

The earliest tracked mention of $REPL in the Surfaced archive was on Jul 22, 2025.

How many voices track $REPL?

2 FinTwit voices have mentioned $REPL 33 times in the past 12 months.

What kind of voices mention $REPL most?

$REPL is mentioned most by Biotech voices on Surfaced.

Last 12mo stats

mentions

voices

$REPL

Q: Who mentions $REPL most on Surfaced?

@adamfeuerstein (Adam Feuerstein ✡️) mentions $REPL most — 29 mentions in the past 12 months.

Replimune Group

$REPL

Replimune Group

Past 12mo:33mentions2voices

All voices11 calls since Jul 2025show all

Loading price chart…

About this stock

Over the past 12 months, $REPL has generated 33 mentions from 2 distinct FinTwit voices, with the first mention appearing on July 22, 2025. The discussion has been dominated by biotech-focused commentary, with @adamfeuerstein accounting for 29 of these mentions and @jacobplieth contributing 5 mentions. The most recent activity occurred on July 7, 2026, when an FDA advisory committee meeting for the company's RP1 candidate was confirmed for July 30, 2026.

AI-generated from tracked posts · updated Jul 9, 2026

Frequently asked

Who mentions $REPL most on Surfaced?

Related stocks

$ALLOAllogene Therapeutics

$ARVNArvinas

$ATRAAtara Biotherapeutics

$BNTXBioNTech SE

Recent calls

11 calls

@adamfeuersteinJul 7, 2026 · 1:43 PM

The FDA adcomm for $REPL RP1 has been scheduled for July 30, according to a notice in the Federal Register. That's one day after the $CAPR deramiocel adcomm on July 29.

Open on X

@adamfeuersteinJun 26, 2026 · 12:56 PM

FDA advisory committee meetings are back. $CAPR deramiocel will be reviewed on July 29, per a notice in the Federal Register. $REPL RP1 will be reviewed in "late July," per the company this morning.

Open on X

@adamfeuersteinMay 29, 2026 · 12:04 PM

$REPL is resubmitting RP1 to the FDA https://t.co/g9sFp9V5bB

Open on X

@adamfeuersteinApr 10, 2026 · 3:24 PM

Replimune $REPL skin cancer drug that became FDA flashpoint is rejected again https://t.co/7aOfKy8vC7 via @Jasonmmast

Open on X

@adamfeuersteinNov 3, 2025 · 12:27 PM

On $QURE: I wrote this in my Sept. 25 newsletter: "Bear in mind: What we have seen so far of the AMT-130 data are mentioned in a Uniqure press release. Fairly detailed, yes, but it will be important to see the data fully presented at a future medical meeting and published in a peer-reviewed journal. The validity of external control arms like the one used by Uniqure is still hotly debated, even as regulators, including the Food and Drug Administration, allow them under certain circumstances. It’s been lost to memory, but recall that the AMT-130 study started with a true, sham-surgery control arm that showed no benefit for the gene therapy. It was only after the company reconfigured the study and started using natural history comparators was a benefit observed." To be clear: I was also very positive on the data and its regulatory stance at the time. I thought this was a gene therapy that would be approved, even with Vinay in charge. That looks wrong now, unless we see another pivot a la $REPL.

Open on X

@adamfeuersteinOct 20, 2025 · 11:05 AM

Wow! $REPL - FDA accepted the resubmission of the RP1 application for advanced melanoma. PDUFA date April 10, 2026.

Open on X

@adamfeuersteinSep 18, 2025 · 2:26 PM

$REPL argument to FDA not yet persuasive, apparently. As I reported earlier, Rick Pazdur's oncology team was strongly against accelerated approval, a position subsequently supported by CBER leadership, even as some reviewers pushed for approval. https://t.co/hQpakAChmZ

Open on X

@adamfeuersteinSep 2, 2025 · 12:05 PM

$REPL schedules FDA meeting https://t.co/w2PwBP9JN5

Open on X

@adamfeuersteinAug 21, 2025 · 12:19 PM

New from me: FDA ‘uncertainty’ forces Krystal Biotech $KRYS to shutter cancer drug trial The decision follows rejection of a similar drug developed by Replimune Group $REPL https://t.co/nY1w3BdmCd

Open on X

@adamfeuersteinAug 4, 2025 · 9:31 AM

FDA’s top cancer drug regulator played key role in rejection of Replimune $REPL therapy, officials say https://t.co/JYjkpdyXXu

Open on X

@adamfeuersteinJul 22, 2025 · 11:47 AM

Replimune $REPL skin cancer therapy rejected by FDA The decision is another signal that the FDA’s top regulator of cell and gene therapies is taking a hardened stance on new drug approvals https://t.co/rBOHATLQnS

Open on X